Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Chief Financial Officer | April 01, 2025 | April 02, 2025 |
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Chief Financial Officer | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date April 01, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,568 |
Ending reported balance
After 2025-04-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-04-01 · Exercise / conversion · Acquired 20,000 · Balance 71,384 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. Row 2 · 2025-04-01 · Sale · Disposed 6,816 · Balance 64,568 F2: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. |
| Employee Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2025-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-01 · Exercise / conversion · Disposed 20,000 · Balance 30,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F3: On April 1, 2023, the reporting person was granted a total of 50,000 RSUs, of which 40% vest on April 1, 2025 and the remaining 60% vest on April 1, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse IRA | 760 |
Reported balance
Holding disclosure · report date 2025-04-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 760 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F2: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
F3: On April 1, 2023, the reporting person was granted a total of 50,000 RSUs, of which 40% vest on April 1, 2025 and the remaining 60% vest on April 1, 2026.
TriSalus Life Sciences, Inc.
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 261,107 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Tax withholding · Disposed 14,650 · Balance 261,107 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 20:01 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | Tax withholdingCommon Stock | 14,650 | $4.46 | $65,339.00 |
DisclosureSEC source: 0001628280-26-047217 · wk-form4_1783368070.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,107 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:42 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 7,100 | $2.43 | $17,253.00 |
DisclosureSEC source: 0001628280-26-035992 · wk-form4_1779136942.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,757 Read SEC document |
| February 23, 2026 Filed Feb 23, 2026 21:08 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 3,657 | $4.10 | $14,993.70 |
DisclosureSEC source: 0001628280-26-010606 · wk-form4_1771880906.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,657 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 20:40 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001970009-25-000004 · wk-form4_1764103242.xml · derivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,899 Underlying: Common Stock · 130,000 shares Expires 2035-11-23 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 20:40 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001970009-25-000004 · wk-form4_1764103242.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,000 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date. Read SEC document |
| August 28, 2025 Filed Aug 29, 2025 20:18 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 248,899 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001826667-25-000131 · wk-form4_1756498688.xml · derivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,899 Underlying: Common Stock · 248,899 shares Expires not disclosed F1 · derivative.exercise_date: Represents the granting of stock options upon achieving or exceeding $75 million of revenue over any twelve (12) consecutive calendar month period ending on or before December 31, 2027. The options vest immediately upon achieving the performance requirement, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. F2 · derivative.expiration_date: The stock options expire on December 31, 2027 if the revenue threshold is not met. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 21:29 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 290,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001826667-25-000121 · wk-form4_1755293353.xml · derivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2035-08-13 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of July 1, 2026 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 21:29 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001826667-25-000121 · wk-form4_1755293353.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on July 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 18:12 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-031298 · tm2511279-1_4seq1.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F3 · derivative.exercise_date: On April 1, 2023, the reporting person was granted a total of 50,000 RSUs, of which 40% vest on April 1, 2025 and the remaining 60% vest on April 1, 2026. F3 · derivative.expiration_date: On April 1, 2023, the reporting person was granted a total of 50,000 RSUs, of which 40% vest on April 1, 2025 and the remaining 60% vest on April 1, 2026. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 18:12 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 6,816 | $0.71 | $4,839.36 |
DisclosureSEC source: 0001104659-25-031298 · tm2511279-1_4seq1.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,568 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 18:12 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-031298 · tm2511279-1_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 19:24 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-018521 · tm257797-1_4seq1.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F3 · derivative.exercise_date: On February 26, 2022, the reporting person was granted a total of 2,500 RSUs, of which 40% vest on February 26, 2024 and the remaining 60% vest on February 26, 2025. F3 · derivative.expiration_date: On February 26, 2022, the reporting person was granted a total of 2,500 RSUs, of which 40% vest on February 26, 2024 and the remaining 60% vest on February 26, 2025. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 19:24 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 535 | $1.09 | $583.15 |
DisclosureSEC source: 0001104659-25-018521 · tm257797-1_4seq1.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,384 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 19:24 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-018521 · tm257797-1_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. Read SEC document |
| May 29, 2024 Filed May 30, 2024 16:15 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Restricted Stock Units · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-066658 · tm2415918-1_4seq1.xml · derivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2 · derivative.exercise_date: On May 29, 2024, the reporting person was granted a total of 120,000 RSUs, of which 40% vest on May 29, 2026 and the remaining 60% vest on May 29, 2027. F2 · derivative.expiration_date: On May 29, 2024, the reporting person was granted a total of 120,000 RSUs, of which 40% vest on May 29, 2026 and the remaining 60% vest on May 29, 2027. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:27 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 37,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-045899 · tm2411517-2_4seq1.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,468 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 5, 2024, the reporting person was granted a total of 37,468 restricted stock units ("RSUs"), which vest on April 9, 2024. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting. F1 · derivative.exercise_date: On March 5, 2024, the reporting person was granted a total of 37,468 restricted stock units ("RSUs"), which vest on April 9, 2024. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting. F1 · derivative.expiration_date: On March 5, 2024, the reporting person was granted a total of 37,468 restricted stock units ("RSUs"), which vest on April 9, 2024. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:27 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 13,296 | $0.87 | $11,567.52 |
DisclosureSEC source: 0001104659-24-045899 · tm2411517-2_4seq1.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,419 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:27 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 37,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-045899 · tm2411517-2_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 5, 2024, the reporting person was granted a total of 37,468 restricted stock units ("RSUs"), which vest on April 9, 2024. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting. F1 · price: On March 5, 2024, the reporting person was granted a total of 37,468 restricted stock units ("RSUs"), which vest on April 9, 2024. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 19:32 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Restricted Stock Units · Derivative | 37,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031600 · tm248096-3_4seq1.xml · derivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,468 Underlying: Common Stock · 37,468 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2 · derivative.exercise_date: On March 5, 2024, the reporting person was granted a total of 37,468 RSUs, which vest on April 9, 2024. F2 · derivative.expiration_date: On March 5, 2024, the reporting person was granted a total of 37,468 RSUs, which vest on April 9, 2024. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 18:59 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028325 · tm247362-1_4seq1.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 26, 2022, the reporting person was granted a total of 2,500 restricted stock units ("RSUs"), of which 40% vest on February 26, 2024 and the remaining 60% vest on February 26, 2025. Each RSU represents a contingent right to receive one share of the issuer's common stock for each RSU upon vesting. F1 · derivative.exercise_date: On February 26, 2022, the reporting person was granted a total of 2,500 restricted stock units ("RSUs"), of which 40% vest on February 26, 2024 and the remaining 60% vest on February 26, 2025. Each RSU represents a contingent right to receive one share of the issuer's common stock for each RSU upon vesting. F1 · derivative.expiration_date: On February 26, 2022, the reporting person was granted a total of 2,500 restricted stock units ("RSUs"), of which 40% vest on February 26, 2024 and the remaining 60% vest on February 26, 2025. Each RSU represents a contingent right to receive one share of the issuer's common stock for each RSU upon vesting. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 18:59 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 350 | $0.96 | $336.00 |
DisclosureSEC source: 0001104659-24-028325 · tm247362-1_4seq1.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,247 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 18:59 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028325 · tm247362-1_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 26, 2022, the reporting person was granted a total of 2,500 restricted stock units ("RSUs"), of which 40% vest on February 26, 2024 and the remaining 60% vest on February 26, 2025. Each RSU represents a contingent right to receive one share of the issuer's common stock for each RSU upon vesting. F1 · price: On February 26, 2022, the reporting person was granted a total of 2,500 restricted stock units ("RSUs"), of which 40% vest on February 26, 2024 and the remaining 60% vest on February 26, 2025. Each RSU represents a contingent right to receive one share of the issuer's common stock for each RSU upon vesting. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:10 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantCommon Stock Warrants (right to buy) · Derivative | 16,666 | Not disclosed Strike: $1.65 | Not disclosed |
DisclosureSEC source: 0001104659-24-006671 · tm244005-1_4seq1.xml · derivative · entry 3 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2029-01-23 F1 · price: The reported securities are included within 16,666 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit from the issuer in an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:10 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantCommon Stock | 16,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-006671 · tm244005-1_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,597 F1 · price: The reported securities are included within 16,666 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit from the issuer in an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 17:14 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-126067 · tm2332887-1_4seq1.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 17:14 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 97 | $4.39 | $425.83 |
DisclosureSEC source: 0001104659-23-126067 · tm2332887-1_4seq1.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,931 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 17:14 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-126067 · tm2332887-1_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 17:02 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-118221 · tm2330666-1_4seq1.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 17:02 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 97 | $5.57 | $540.29 |
DisclosureSEC source: 0001104659-23-118221 · tm2330666-1_4seq1.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,697 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 17:02 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-118221 · tm2330666-1_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 17:17 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034442 · wk-form4_1697491053.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 17:17 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 96 | $5.83 | $559.68 |
DisclosureSEC source: 0001628280-23-034442 · wk-form4_1697491053.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,463 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 17:17 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034442 · wk-form4_1697491053.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 16:11 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-100789 · tm2326124-1_4seq1.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 16:11 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 96 | $6.53 | $626.88 |
DisclosureSEC source: 0001104659-23-100789 · tm2326124-1_4seq1.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,228 F2 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 16:11 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-100789 · tm2326124-1_4seq1.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The reporting person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of the issuer's common stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 RSUs, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 19:22 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 95 | $6.80 | $646.00 |
DisclosureSEC source: 0001628280-23-029596 · wk-form4_1692141711.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,993 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| August 13, 2023 Filed Aug 15, 2023 19:22 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029596 · wk-form4_1692141711.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,324 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| August 13, 2023 Filed Aug 15, 2023 19:22 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029596 · wk-form4_1692141711.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 17:20 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 330 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-025009 · wk-form4_1689628810.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,655 Underlying: Common Stock · 330 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 17:20 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 92 | $6.90 | $634.80 |
DisclosureSEC source: 0001628280-23-025009 · wk-form4_1689628810.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,757 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 13, 2023 Filed Jul 17, 2023 17:20 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 330 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-025009 · wk-form4_1689628810.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 3,970 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| June 18, 2023 Filed Jun 20, 2023 17:41 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Restricted Stock Units · Derivative | 611,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022764 · wk-form4_1687297248.xml · derivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,842 Underlying: Common Stock · 611,842 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The reporting person received 611,842 restricted stock units on June 18, 2023, of which 40% vests on June 18, 2025 and the remaining 60% will vest on June 18, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 13:19 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 3,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022178 · wk-form4_1686849552.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,853 Underlying: Common Stock · 3,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 13:19 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 1,287 | $0.90 | $1,158.30 |
DisclosureSEC source: 0001628280-23-022178 · wk-form4_1686849552.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,192 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 13:19 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 3,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022178 · wk-form4_1686849552.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 17:38 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 3,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-018496 · wk-form4_1684273088.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,162 Underlying: Common Stock · 3,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 17:38 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | SaleCommon Stock | 1,222 | $0.69 | $843.18 |
DisclosureSEC source: 0001628280-23-018496 · wk-form4_1684273088.xml · nonDerivative · entry 2 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,170 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| May 15, 2023 Filed May 16, 2023 17:38 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 3,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-018496 · wk-form4_1684273088.xml · nonDerivative · entry 1 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 21:54 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionEmployee Restricted Stock Units · Derivative | 3,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-011840 · wf-form4_168178287326590.xml · derivative · entry 4 Patience David · CIK 0001970009 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,471 Underlying: Common Stock · 3,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 39,707 restricted stock units, which vests in equal amounts every month for 12 months, which started vesting on January 13, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.